Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Long-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
Long-term activity ratio | Description | The company |
---|---|---|
Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Vertex Pharmaceuticals Inc. net fixed asset turnover ratio improved from Q2 2023 to Q3 2023 but then slightly deteriorated from Q3 2023 to Q4 2023 not reaching Q2 2023 level. |
Net fixed asset turnover (including operating lease, right-of-use asset) | An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). | Vertex Pharmaceuticals Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Vertex Pharmaceuticals Inc. total asset turnover ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | Vertex Pharmaceuticals Inc. equity turnover ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Net Fixed Asset Turnover
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
Revenues | 2,517,700) | 2,483,500) | 2,493,200) | 2,374,800) | 2,302,700) | 2,334,300) | 2,196,200) | 2,097,500) | 2,072,561) | 1,984,164) | 1,793,370) | 1,724,305) | 1,627,820) | 1,538,271) | 1,524,485) | 1,515,107) | 1,413,265) | 949,828) | 941,293) | 858,435) | ||||||
Property and equipment, net | 1,159,300) | 1,124,000) | 1,122,400) | 1,111,700) | 1,108,400) | 1,118,700) | 1,100,100) | 1,107,400) | 1,094,100) | 1,042,347) | 1,021,233) | 986,123) | 958,534) | 920,913) | 728,357) | 736,303) | 745,080) | 733,509) | 731,131) | 742,559) | ||||||
Long-term Activity Ratio | ||||||||||||||||||||||||||
Net fixed asset turnover1 | 8.51 | 8.59 | 8.47 | 8.28 | 8.06 | 7.78 | 7.59 | 7.18 | 6.92 | 6.84 | 6.54 | 6.51 | 6.47 | 6.51 | 7.42 | 6.55 | 5.59 | — | — | — | ||||||
Benchmarks | ||||||||||||||||||||||||||
Net Fixed Asset Turnover, Competitors2 | ||||||||||||||||||||||||||
AbbVie Inc. | 10.89 | 11.18 | 11.33 | 11.51 | 11.76 | 11.82 | 11.57 | 11.18 | 11.00 | 10.75 | 10.41 | 9.67 | 8.73 | 8.15 | 7.38 | 11.50 | 11.23 | — | — | — | ||||||
Amgen Inc. | 4.53 | 4.61 | 4.58 | 4.56 | 4.57 | 4.73 | 4.77 | 4.75 | 4.69 | 4.89 | 4.92 | 4.93 | 4.96 | 4.94 | 4.78 | 4.68 | 4.51 | — | — | — | ||||||
Bristol-Myers Squibb Co. | 6.77 | 6.93 | 7.11 | 7.30 | 7.38 | 7.74 | 7.90 | 7.77 | 7.67 | 7.75 | 7.66 | 7.43 | 7.22 | 6.86 | 6.03 | 5.07 | 4.18 | — | — | — | ||||||
Danaher Corp. | 5.25 | 6.01 | 6.68 | 7.31 | 7.96 | 8.40 | 8.12 | 7.94 | 7.77 | 7.71 | 7.84 | 7.59 | 6.83 | 6.68 | 6.35 | 6.03 | 7.78 | — | — | — | ||||||
Eli Lilly & Co. | 2.64 | 2.70 | 2.62 | 2.63 | 2.81 | 3.14 | 3.18 | 3.22 | 3.15 | 3.11 | 3.02 | 2.95 | 2.83 | 2.80 | 2.88 | 2.92 | 2.83 | — | — | — | ||||||
Gilead Sciences Inc. | 5.07 | 4.88 | 4.91 | 4.88 | 4.93 | 5.01 | 5.13 | 5.18 | 5.27 | 5.40 | 5.27 | 5.06 | 4.90 | 4.74 | 4.70 | 4.90 | 4.91 | — | — | — | ||||||
Johnson & Johnson | 4.28 | 4.65 | 4.37 | 4.58 | 4.79 | 5.29 | 5.21 | 5.07 | 4.95 | 4.95 | 4.79 | 4.59 | 4.40 | 4.53 | 4.57 | 4.75 | 4.65 | — | — | — | ||||||
Merck & Co. Inc. | 2.61 | 2.63 | 2.62 | 2.66 | 2.77 | 2.89 | 2.85 | 2.73 | 2.53 | 2.57 | 2.61 | 2.55 | 2.67 | 2.80 | 2.99 | 3.15 | 3.11 | — | — | — | ||||||
Pfizer Inc. | 3.14 | 3.88 | 4.48 | 5.46 | 6.17 | 6.47 | 6.64 | 6.12 | 5.46 | 4.79 | 3.89 | 3.31 | 3.01 | 2.98 | 3.21 | 3.47 | 3.71 | — | — | — | ||||||
Regeneron Pharmaceuticals Inc. | 3.16 | 3.27 | 3.23 | 3.19 | 3.23 | 3.70 | 3.91 | 4.64 | 4.62 | 3.99 | 3.69 | 2.82 | 2.64 | 2.63 | 2.64 | 2.71 | 2.72 | — | — | — | ||||||
Thermo Fisher Scientific Inc. | 4.54 | 4.74 | 4.68 | 4.68 | 4.84 | 5.12 | 5.02 | 4.87 | 4.71 | 5.54 | 5.83 | 5.85 | 5.45 | 5.50 | 5.37 | 5.42 | 5.38 | — | — | — |
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Net fixed asset turnover
= (RevenuesQ4 2023
+ RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023)
÷ Property and equipment, net
= (2,517,700 + 2,483,500 + 2,493,200 + 2,374,800)
÷ 1,159,300 = 8.51
2 Click competitor name to see calculations.
Long-term activity ratio | Description | The company |
---|---|---|
Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Vertex Pharmaceuticals Inc. net fixed asset turnover ratio improved from Q2 2023 to Q3 2023 but then slightly deteriorated from Q3 2023 to Q4 2023 not reaching Q2 2023 level. |
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)
Vertex Pharmaceuticals Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation (quarterly data)
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset)
= (RevenuesQ4 2023
+ RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023)
÷ Property and equipment, net (including operating lease, right-of-use asset)
= (2,517,700 + 2,483,500 + 2,493,200 + 2,374,800)
÷ 1,452,900 = 6.79
Long-term activity ratio | Description | The company |
---|---|---|
Net fixed asset turnover (including operating lease, right-of-use asset) | An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). | Vertex Pharmaceuticals Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Total Asset Turnover
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
Revenues | 2,517,700) | 2,483,500) | 2,493,200) | 2,374,800) | 2,302,700) | 2,334,300) | 2,196,200) | 2,097,500) | 2,072,561) | 1,984,164) | 1,793,370) | 1,724,305) | 1,627,820) | 1,538,271) | 1,524,485) | 1,515,107) | 1,413,265) | 949,828) | 941,293) | 858,435) | ||||||
Total assets | 22,730,200) | 21,726,200) | 20,349,200) | 18,974,200) | 18,150,900) | 16,706,400) | 15,582,200) | 14,256,100) | 13,432,500) | 12,618,745) | 12,221,686) | 12,115,059) | 11,751,808) | 11,301,633) | 10,216,367) | 8,893,201) | 8,318,465) | 7,514,553) | 7,033,471) | 6,543,114) | ||||||
Long-term Activity Ratio | ||||||||||||||||||||||||||
Total asset turnover1 | 0.43 | 0.44 | 0.47 | 0.49 | 0.49 | 0.52 | 0.54 | 0.56 | 0.56 | 0.57 | 0.55 | 0.53 | 0.53 | 0.53 | 0.53 | 0.54 | 0.50 | — | — | — | ||||||
Benchmarks | ||||||||||||||||||||||||||
Total Asset Turnover, Competitors2 | ||||||||||||||||||||||||||
AbbVie Inc. | 0.40 | 0.40 | 0.41 | 0.42 | 0.42 | 0.41 | 0.40 | 0.40 | 0.38 | 0.37 | 0.36 | 0.33 | 0.30 | 0.27 | 0.24 | 0.37 | 0.37 | — | — | — | ||||||
Amgen Inc. | 0.28 | 0.28 | 0.28 | 0.28 | 0.38 | 0.38 | 0.41 | 0.41 | 0.40 | 0.37 | 0.40 | 0.38 | 0.39 | 0.37 | 0.36 | 0.37 | 0.37 | — | — | — | ||||||
Bristol-Myers Squibb Co. | 0.47 | 0.49 | 0.48 | 0.49 | 0.48 | 0.48 | 0.47 | 0.46 | 0.42 | 0.41 | 0.40 | 0.38 | 0.36 | 0.31 | 0.27 | 0.24 | 0.20 | — | — | — | ||||||
Danaher Corp. | 0.28 | 0.29 | 0.33 | 0.35 | 0.37 | 0.39 | 0.38 | 0.36 | 0.35 | 0.34 | 0.34 | 0.33 | 0.29 | 0.28 | 0.27 | 0.26 | 0.29 | — | — | — | ||||||
Eli Lilly & Co. | 0.53 | 0.55 | 0.54 | 0.52 | 0.58 | 0.62 | 0.62 | 0.62 | 0.58 | 0.58 | 0.56 | 0.54 | 0.53 | 0.53 | 0.55 | 0.56 | 0.57 | — | — | — | ||||||
Gilead Sciences Inc. | 0.43 | 0.44 | 0.44 | 0.43 | 0.43 | 0.43 | 0.43 | 0.43 | 0.40 | 0.41 | 0.39 | 0.37 | 0.36 | 0.37 | 0.39 | 0.37 | 0.36 | — | — | — | ||||||
Johnson & Johnson | 0.51 | 0.53 | 0.47 | 0.47 | 0.51 | 0.55 | 0.54 | 0.53 | 0.52 | 0.51 | 0.51 | 0.49 | 0.47 | 0.47 | 0.51 | 0.53 | 0.52 | — | — | — | ||||||
Merck & Co. Inc. | 0.56 | 0.56 | 0.56 | 0.54 | 0.54 | 0.55 | 0.53 | 0.51 | 0.46 | 0.51 | 0.52 | 0.51 | 0.52 | 0.53 | 0.52 | 0.57 | 0.55 | — | — | — | ||||||
Pfizer Inc. | 0.26 | 0.32 | 0.36 | 0.48 | 0.51 | 0.51 | 0.52 | 0.50 | 0.45 | 0.39 | 0.33 | 0.29 | 0.27 | 0.24 | 0.25 | 0.29 | 0.31 | — | — | — | ||||||
Regeneron Pharmaceuticals Inc. | 0.40 | 0.41 | 0.41 | 0.41 | 0.42 | 0.50 | 0.52 | 0.63 | 0.63 | 0.57 | 0.58 | 0.52 | 0.50 | 0.51 | 0.55 | 0.51 | 0.53 | — | — | — | ||||||
Thermo Fisher Scientific Inc. | 0.43 | 0.45 | 0.46 | 0.46 | 0.46 | 0.49 | 0.47 | 0.44 | 0.41 | 0.53 | 0.57 | 0.54 | 0.47 | 0.44 | 0.43 | 0.44 | 0.44 | — | — | — |
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Total asset turnover
= (RevenuesQ4 2023
+ RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023)
÷ Total assets
= (2,517,700 + 2,483,500 + 2,493,200 + 2,374,800)
÷ 22,730,200 = 0.43
2 Click competitor name to see calculations.
Long-term activity ratio | Description | The company |
---|---|---|
Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Vertex Pharmaceuticals Inc. total asset turnover ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Equity Turnover
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
Revenues | 2,517,700) | 2,483,500) | 2,493,200) | 2,374,800) | 2,302,700) | 2,334,300) | 2,196,200) | 2,097,500) | 2,072,561) | 1,984,164) | 1,793,370) | 1,724,305) | 1,627,820) | 1,538,271) | 1,524,485) | 1,515,107) | 1,413,265) | 949,828) | 941,293) | 858,435) | ||||||
Shareholders’ equity | 17,580,400) | 16,512,800) | 15,470,200) | 14,432,300) | 13,912,700) | 13,029,600) | 11,933,500) | 10,907,000) | 10,100,000) | 9,530,708) | 9,196,396) | 8,980,254) | 8,686,815) | 8,133,473) | 7,519,242) | 6,461,654) | 6,085,244) | 5,253,394) | 5,069,965) | 4,723,313) | ||||||
Long-term Activity Ratio | ||||||||||||||||||||||||||
Equity turnover1 | 0.56 | 0.58 | 0.61 | 0.64 | 0.64 | 0.67 | 0.70 | 0.73 | 0.75 | 0.75 | 0.73 | 0.71 | 0.71 | 0.74 | 0.72 | 0.75 | 0.68 | — | — | — | ||||||
Benchmarks | ||||||||||||||||||||||||||
Equity Turnover, Competitors2 | ||||||||||||||||||||||||||
AbbVie Inc. | 5.24 | 4.56 | 4.35 | 4.27 | 3.36 | 3.62 | 3.91 | 3.48 | 3.65 | 4.07 | 4.27 | 3.66 | 3.50 | 2.66 | 2.46 | — | — | — | — | — | ||||||
Amgen Inc. | 4.32 | 3.35 | 3.73 | 4.66 | 6.77 | 6.71 | 10.17 | 26.68 | 3.63 | 2.96 | 2.93 | 2.56 | 2.58 | 2.17 | 2.17 | 2.41 | 2.30 | — | — | — | ||||||
Bristol-Myers Squibb Co. | 1.53 | 1.55 | 1.41 | 1.44 | 1.49 | 1.43 | 1.45 | 1.49 | 1.29 | 1.22 | 1.21 | 1.14 | 1.12 | 0.79 | 0.71 | 0.62 | 0.51 | — | — | — | ||||||
Danaher Corp. | 0.45 | 0.49 | 0.54 | 0.58 | 0.63 | 0.67 | 0.66 | 0.65 | 0.65 | 0.65 | 0.62 | 0.61 | 0.56 | 0.54 | 0.52 | 0.58 | 0.59 | — | — | — | ||||||
Eli Lilly & Co. | 3.17 | 2.86 | 2.67 | 2.47 | 2.68 | 2.90 | 3.40 | 3.14 | 3.15 | 3.58 | 4.15 | 3.69 | 4.35 | 4.81 | 5.61 | 7.50 | 8.56 | — | — | — | ||||||
Gilead Sciences Inc. | 1.18 | 1.22 | 1.28 | 1.27 | 1.27 | 1.27 | 1.34 | 1.37 | 1.28 | 1.27 | 1.34 | 1.33 | 1.34 | 1.31 | 1.21 | 1.01 | 0.98 | — | — | — | ||||||
Johnson & Johnson | 1.24 | 1.23 | 1.20 | 1.30 | 1.24 | 1.29 | 1.25 | 1.27 | 1.27 | 1.30 | 1.28 | 1.28 | 1.31 | 1.25 | 1.28 | 1.35 | 1.38 | — | — | — | ||||||
Merck & Co. Inc. | 1.60 | 1.44 | 1.51 | 1.24 | 1.29 | 1.33 | 1.32 | 1.32 | 1.28 | 1.33 | 1.41 | 1.73 | 1.90 | 1.62 | 1.71 | 1.83 | 1.81 | — | — | — | ||||||
Pfizer Inc. | 0.67 | 0.71 | 0.79 | 0.92 | 1.05 | 1.08 | 1.16 | 1.12 | 1.05 | 0.91 | 0.79 | 0.68 | 0.66 | 0.66 | 0.70 | 0.75 | 0.82 | — | — | — | ||||||
Regeneron Pharmaceuticals Inc. | 0.51 | 0.53 | 0.53 | 0.53 | 0.54 | 0.64 | 0.69 | 0.83 | 0.86 | 0.78 | 0.82 | 0.77 | 0.77 | 0.81 | 0.88 | 0.66 | 0.71 | — | — | — | ||||||
Thermo Fisher Scientific Inc. | 0.92 | 0.96 | 0.99 | 1.04 | 1.02 | 1.01 | 1.01 | 1.00 | 0.96 | 1.01 | 1.04 | 1.02 | 0.93 | 0.90 | 0.88 | 0.90 | 0.86 | — | — | — |
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Equity turnover
= (RevenuesQ4 2023
+ RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023)
÷ Shareholders’ equity
= (2,517,700 + 2,483,500 + 2,493,200 + 2,374,800)
÷ 17,580,400 = 0.56
2 Click competitor name to see calculations.
Long-term activity ratio | Description | The company |
---|---|---|
Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | Vertex Pharmaceuticals Inc. equity turnover ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |